OBJECTIVES: This study estimates the annual treatment cost of Jivi® compared to other EHL treatments in hemophilia A, Adynovate, Eloctate, and Esperoct, for patients aged 12 years and above, from a US payer perspective.

METHODS: A prevalence-based cost model was developed in MS Excel and delivered as interactive web tool. The model estimates annual utilization and cost of Jivi® given a patient-mix with two regimens, 50% of patients – every 5 days and mean of 52.5 IU/kg/Inj; 50% – twice weekly and mean of 35 IU/kg/Inj, and compares to the utilization and costs of other EHL treatments available in the US for routine prophylaxis. Annual treatment cost results are calculated considering mid-point IU per injection and frequency of administration from FDA USPI. We assumed an average patient weight of 73 kg and a 2021 WAC price per IU of $2.31, $2.22, $2.30, $2.30 for Jivi®, Adynovate, Esperoct, Eloctate respectively. One-way sensitivity analysis was conducted to characterize parametric uncertainty around mean inputs.

RESULTS: When comparing across all EHLs, Jivi® results in 273,111 IU per year, which represents 59,951 – 69,467 IU lower per patient annual utilization. The annual treatment costs associated with Jivi® were estimated to be $129,637 – $135,157 lower compared to the other EHLs. The lower annual utilization and treatment costs with Jivi® are also confirmed in scenario analyses where all patients are on the highest consumption regimen of Jivi® as per recommended in the package insert.

CONCLUSIONS: This interactive tool, using information from recommended dosage and administration per USPI, illustrates the lower annual utilization of Jivi® resulting in a less costly option compared to other EHLs for patients aged 12 years and above treated by prophylaxis in the US.